188 jili turnover

188 jili turnover AltC Acquisition (NYSE: ALCC) disclosed in a recent 8-K filing that its Compensation Committee has approved salary increases for key executives. The Board of Directors approved the raises for Jacob DeWitte, the Chief Executive Officer, and R. Craig Bealmear, the Chief Financial Officer, increasing their annual base salaries from $500,000 to $625,000 and from $400,000 to $440,000, respectively. Additionally, the Committee raised the annual target bonus opportunities for the executives and the Chief Operating Officer Caroline Cochran from 50% to 65% of their base salaries, effective from January 1, 2025. The filing, dated December 27, 2024, under Item 5.02 of Departure of Directors or Certain Officers, outlines the adjusted compensation for the executive team. These changes in compensation packages reflect the company’s efforts to retain and motivate its leadership amidst evolving market conditions. The agreement detailed in the filing underscores the commitment of AltC Acquisition to rewarding and retaining talent crucial to driving the company’s growth strategy. Such adjustments in executive compensation are often seen as strategic moves to align leadership incentives with corporate objectives and shareholder interests. The Company’s decision reflects an ongoing trend in the industry where companies strive to attract and retain top talent in a competitive market landscape. These adjustments may signal a strong outlook for AltC Acquisition and a strategic approach to rewarding its key leadership team. The company’s initiative to increase executive compensation is subject to the approvals outlined in the filing and is aimed at enhancing performance and aligning incentives with the company’s long-term objectives. This article is a summary based on the information provided in AltC Acquisition’s recent 8-K filing and is in compliance with the regulations governing the disclosure of material information to shareholders and the investing public. This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read AltC Acquisition’s 8K filing here . AltC Acquisition Company Profile ( Get Free Report ) AltC Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was formerly known as Churchill Capital Corp VIII and changed its name to AltC Acquisition Corp. Recommended StoriesDowning throws for 2 TDs, runs for another, Elon tops North Carolina A&T 31-21Saquon Barkley tops 2,000 yards rushing as Eagles beat Cowboys 41-7 to clinch NFC East

TOKYO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that M3, Inc. (TOKYO PRIME: 2413), or an affiliate within the M3 group, is participating in the Series A equity financing round of MEDIROM MOTHER Labs Inc., a subsidiary of MEDIROM. NFES Technologies Inc. is the lead investor of the Series A financing round at a pre-money valuation of JPY9 billion. Additional information is available here: https://medirom.co.jp/en/ir/20240824/6148%09 Forward-Looking Statements Regarding MEDIROM Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about MEDIROM’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to MEDIROM’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause MEDIROM’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond MEDIROM’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects MEDIROM’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MEDIROM’s operations, results of operations, growth strategy and liquidity. More information on these risks and other potential factors that could affect MEDIROM’s business, reputation, results of operations, financial condition, and stock price is included in MEDIROM’s filings with the Securities and Exchange Commission (the “SEC”), including in the “Risk Factors” and “Operating and Financial Review and Prospects” sections of MEDIROM’s most recently filed periodic report on Form 20-F and subsequent filings, which are available on the SEC website at www.sec.gov . MEDIROM assumes no obligation to update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ from those anticipated in these forward-looking statements, even if new information becomes available in the future. ABOUT M3, Inc. M3 is a one of a kind venture company that operates a multitude of global services centred around its physician platform such as m3.com . M3 is the first company incorporated after the year 2000 to be included in the Nikkei 225 Index. Its 330,000+ Japanese and 6,500,000+ global physician member panel serves as a central platform in advancing innovation and reform across healthcare worldwide. Tokyo Stock Exchange Prime Market (Securities code 2413) 1-11-44 Akasaka Minato-ku, Tokyo 107-0052 JAPAN Web https://corporate.m3.com/en ABOUT MEDIROM MOTHER Labs Inc. A subsidiary of MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), focuses on the health-tech sector. The company’s core activities include the "Specific Health Guidance Program" offered through the "Lav" health application and development and sales of the 24/7 recharge-free MOTHER Bracelet smart tracker. By leveraging the features of the recharge-free MOTHER Bracelet, MOTHER Labs offers customizable health management solutions across diverse sectors, including caregiving, logistics, manufacturing, etc. MEDIROM Healthcare Technologies Inc. NASDAQ Symbol: MRM Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan Web https://medirom.co.jp/en Contact: ir@medirom.co.jp MEDIROM MOTHER Labs Inc. Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan MOTHER Bracelet is the world's first* 24/7 recharge-free smart tracker. It uses innovative technology from a Silicon Valley tech company that allows for power generation based on temperature differences between body and surrounding air. The recharge-free feature eliminates the risk of data loss when a device is taken off for recharge. MOTHER Bracelet records five basic metrics: heart rate, calories burned, body surface temperature, step count, and sleep. Official Website: https://mother-bracelet.comAtalanta goes from the Europa League trophy to the top of Serie A. Inter routs Verona 5-0

Jalen Johnson scores 28 to lead the Hawks over the Bulls 120-110

Ina Garten Denies Martha Stewart's Claim About Their Falling OutU.S. stocks climbed after market superstar Nvidia and another round of companies said they’re making even fatter profits than expected. The S&P 500 pulled 0.5% higher Thursday after flipping between modest gains and losses several times in the morning. The Dow Jones Industrial Average jumped 1.1%, and the Nasdaq composite edged up less than 0.1%. Banks, smaller companies and other areas of the stock market that tend to do best when the economy is strong helped lead the way, while bitcoin briefly broke above $99,000. Crude oil, meanwhile, continued to rise. Treasury yields edged higher in the bond market. On Thursday: The S&P 500 rose 31.60 points, or 0.5%, to 5,948.71. The Dow Jones Industrial Average rose 461.88 points, or 1.1%, to 43,870.35. The Nasdaq composite rose 6.28 points, or less than 0.1%, to 18,972.42. The Russell 2000 index of smaller companies rose 38.48 points, or 1.7%, to 2,364.02. For the week: The S&P 500 is up 78.09 points, or 1.3%. The Dow is up 425.36 points, or 1%. The Nasdaq is up 292.30 points, or 1.6%. The Russell 2000 is up 60.18 points, or 2.6%. For the year: The S&P 500 is up 1,178.88 points, or 24.7%. The Dow is up 6,180.81 points, or 16.4%. The Nasdaq is up 3,961.07 points, or 26.4%. The Russell 2000 is up 336.94 points, or 16.6%.Packers fail yet again to produce a premier performance against a top NFC team in loss to Vikings

Innovid Corp. ( NYSE:CTV – Get Free Report ) was the recipient of a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 355,000 shares, a drop of 33.7% from the November 30th total of 535,200 shares. Based on an average daily trading volume, of 1,970,000 shares, the short-interest ratio is currently 0.2 days. Approximately 0.4% of the shares of the company are sold short. Wall Street Analysts Forecast Growth A number of equities analysts have commented on the stock. Citizens Jmp downgraded shares of Innovid from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 21st. JMP Securities downgraded shares of Innovid from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 21st. Finally, Needham & Company LLC reiterated a “hold” rating and set a $3.00 target price on shares of Innovid in a research report on Friday, November 22nd. Four analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Innovid presently has an average rating of “Hold” and a consensus price target of $2.83. Get Our Latest Stock Analysis on Innovid Institutional Investors Weigh In On Innovid Innovid Trading Down 0.6 % Shares of Innovid stock opened at $3.09 on Friday. The stock has a market cap of $458.78 million, a PE ratio of -34.33 and a beta of 3.30. The company has a 50-day moving average of $2.51 and a two-hundred day moving average of $2.06. Innovid has a 12-month low of $1.25 and a 12-month high of $3.40. About Innovid ( Get Free Report ) Innovid Corp. operates an independent software platform that provides ad serving, measurement, and creative services. It offers advertising services for the creation, delivery, and measurement of TV ads across connected TV, mobile TV, and desktop TV environments to advertisers, publishers, and media agencies. See Also Receive News & Ratings for Innovid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovid and related companies with MarketBeat.com's FREE daily email newsletter .

Dow ends at fresh record as weak eurozone data hits euro

Reliance Power Share Price Today: Rs 3760 Cr Loan For Anil Ambani's Company - Details

Bioinformatics Services Market 2024 Opportunity Assessment, Production Analysis, Segmentation And Forecast To 2033 11-23-2024 01:23 PM CET | Advertising, Media Consulting, Marketing Research Press release from: The Business Research Company Bioinformatics Services Market Growth The Business Research Company recently released a comprehensive report on the Global Bioinformatics Services Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. According to The Business Research Company's, The bioinformatics services market size has grown rapidly in recent years. It will grow from $3.68 billion in 2023 to $4.24 billion in 2024 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to genomic research advancements, rise in personalized medicine, pharmaceutical r&d investments, biological data explosion, government initiatives in healthcare, increasing adoption of next-generation sequencing (ngs). The bioinformatics services market size is expected to see rapid growth in the next few years. It will grow to $7.83 billion in 2028 at a compound annual growth rate (CAGR) of 16.6%. The growth in the forecast period can be attributed to expanding role in clinical diagnostics, growing importance in agriculture and environmental sciences, increasing collaboration in research, rising demand in drug repurposing. Major trends in the forecast period include digital health initiatives, technological advancements in sequencing, ai and machine learning integration, cloud-based solutions, personalized medicine and genomic analysis, integration of blockchain for data security. Get The Complete Scope Of The Report @ https://www.thebusinessresearchcompany.com/report/bioinformatics-services-global-market-report Market Drivers and Trends: The increasing use of information technology in healthcare is expected to propel the growth of the bioinformatics services market going forward. The increased use of information technology in healthcare has assisted healthcare practitioners in improving the quality of treatment they provide to patients, improving patient safety, increasing efficiency, lowering costs, and improving communication among healthcare professionals. Bioinformatics services, which involve the use of computer science and statistics for analyzing biological data, depend heavily on information technology (IT). For instance, in August 2021, according to the and Life Sciences Experience Survey, a Europe-based company specializing in information technology consulting and services, only 7% of consumers had a virtual consultation with a provider in early 2020, compared to 32% this in 2021. There was also an increase in the use of electronic health records, with 31% of patient group using EHR in 2021. Remote patient monitoring also increased since the previous pre-pandemic assessment. Therefore, the increasing use of information technology in healthcare is driving the growth of the bioinformatics services market going forward. Technological advancements are a key trend gaining popularity in the bioinformatics services market. Companies operating in the bioinformatics services market are adopting new technologies to sustain their position in the market. For instance, in July 2022, bitBiome Inc., a Japan-based microbiome analysis company, launched the Enzyme Discovery service. Enzyme Discovery Service is based on the globe's largest microbial genome database (MMGDB) and unique bioinformatics technologies. To create the MMGDB, bitBiome employs its fundamental technology, bit-MAP, a microbial single-cell genome analysis technique, to analyze the human microbiome as well as the environmental bacteria living in soil, the ocean, and hot springs. With its unique bioinformatics and 3D structural modeling technologies, BitBiome provides enzyme discovery services such as searching for optimal sequences from the MMGDB. Key Benefits for Stakeholders: • Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry. • Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning. • Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition. • Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights. • Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale. Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=10110&type=smp Major Key Players of the Market: QIAGEN Digital Insights; Thermo Fisher Scientific Inc.; Illumina Inc.; DNAnexus Inc.; PerkinElmer Inc.; Biomax Informatics AG; Life Technologies Corporation; BGI Group; Eurofins Scientific SE; NeoGenomics Laboratories Inc.; CD Genomics Inc.; MedGenome Labs Pvt. Ltd.; Fios Genomics Ltd.; Geneva Bioinformatics SA; GVK Biosciences Private Limited; Accelrys Inc.; Macrogen Inc.; GENEWIZ Inc.; Source BioScience Limited; Microsynth AG; BaseClear B.V.; DNASTAR Inc.; GATC Biotech AG; Partek Incorporated; Seven Bridges Genomics Inc.; Omixon Inc.; BioTeam Inc.; BioBam Bioinformatics S.L.; Biomatters Limited; Genomatix GmbH; DNASTREAM Limited; Genalice B.V.; Golden Helix Inc.; Strand Life Sciences Private Limited Bioinformatics Services Market 2024 Key Insights: • The bioinformatics services market size will grow to $7.83 billion in 2028 at a compound annual growth rate (CAGR) of 16.6%. • Rising Adoption Of Information Technology Fuels Growth In Bioinformatics Services Market • Cutting-Edge Technologies Reshapes Bioinformatics Services • North America was the largest region in the bioinformatics services market in 2023 We Offer Customized Report, Click @ https://www.thebusinessresearchcompany.com/Customise?id=10110&type=smp Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: info@tbrc.info Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model Learn More About The Business Research Company The Business Research Company ( www.thebusinessresearchcompany.com ) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide. This release was published on openPR.